文献速递胸部肿瘤骨软组织肉瘤与黑色素瘤泌尿男性生殖肿瘤

80岁及以上癌症患者接受单药免疫检查点抑制剂治疗的临床结局与毒性反应:一项多中心国际队列研究

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项多中心国际回顾性研究纳入2010至2019年间18个学术中心收治的928例接受单药免疫检查点抑制剂(ICI)治疗的80岁及以上癌症患者,分析其临床结局与免疫相关不良事件(irAE)。结果显示ICI在老年患者中可能有效且总体耐受良好,但90岁及以上患者因irAE停药的比例显著高于90岁以下患者(30.9% vs 15.1%,P=.008)。

要点

  • 928例80岁及以上患者接受单药ICI,非小细胞肺癌、黑色素瘤和泌尿生殖系统肿瘤的客观缓解率分别为32.2%、39.3%和26.2%。
  • 41.3%的患者发生至少1种irAE,12.2%为3至4级;irAE中位发生时间为9.8周,57%发生在治疗开始后3个月内。
  • 90岁及以上患者因irAE停药的比例为30.9%,显著高于90岁以下患者的15.1%(P=.008)。

核心结论

  • 这项国际队列研究提示,ICI治疗在老年癌症患者中可能有效且总体耐受良好,但因irAE停药随年龄增长而更常见。

研究设计与样本

  • 多中心、国际回顾性研究,纳入2010至2019年间来自美国和欧洲18个学术中心的928例接受单药ICI治疗的不同肿瘤老年患者,分析于2021年1月至2021年4月进行。

主要发现

  • 928例患者开始ICI治疗时的中位年龄(范围)为83.0(75.8-97.0)岁,806例(86.9%)接受抗程序性细胞死亡1治疗。
  • 非小细胞肺癌、黑色素瘤和泌尿生殖系统肿瘤的客观缓解率分别为32.2%、39.3%和26.2%。
  • 非小细胞肺癌、黑色素瘤和泌尿生殖系统肿瘤的中位无进展生存期分别为6.7、11.1和6.0个月,中位总生存期分别为10.9、30.0和15.0个月。
  • 在组织学特定亚组(非小细胞肺癌、黑色素瘤和泌尿生殖系统肿瘤)内,年龄亚组(<85岁 vs ≥85岁)的临床结局相似。
  • 全部928例患者中,383例(41.3%)发生至少1种irAE,其中113例(12.2%)根据不良事件通用术语标准(5.0版)报告为3至4级;irAE中位发生时间为9.8周,219例(57%)发生在ICI开始后3个月内;137例(16.1%)因irAE停止ICI治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Geriatric (aged ≥80 years) patients are historically underrepresented in cancer clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) in geriatric patients. These agents are associated with immune-related adverse events (irAEs), which may be particularly associated with morbidity in this population. OBJECTIVE: To provide insight into the clinical outcomes and safety of ICIs among geriatric patients (aged ≥80 years) with cancer. DESIGN, SETTING, AND PARTICIPANTS: A Multicenter, international retrospective study of 928 geriatric patients with different tumors treated with single-agent ICIs between 2010 to 2019 from 18 academic centers in the US and Europe. Analyses were conducted from January 2021 to April 2021. MAIN OUTCOMES AND MEASURES: Clinical outcomes and irAE patterns in geriatric patients treated with single-agent ICIs. RESULTS: Median (range) age of the 928 patients at ICI initiation was 83.0 (75.8-97.0) years. Most patients (806 [86.9%]) were treated with anti-programmed cell death 1 therapy. Among the full cohort, the 3 most common tumors were non-small cell lung cancer (NSCLC, 345 [37.2%]), melanoma (329 [35.5%]), and genitourinary (GU) tumors (153 [16.5%]). Objective response rates for patients with NSCLC, melanoma, and GU tumors were 32.2%, 39.3%, and 26.2%, respectively. Median PFS and OS, respectively, were 6.7 and 10.9 months (NSCLC), 11.1 and 30.0 months (melanoma), and 6.0 and 15.0 months (GU). Within histologically specific subgroups (NSCLC, melanoma, and GU), clinical outcomes were similar across age subgroups (aged <85 vs ≥85 years). Among all 928 patients, 383 (41.3%) experienced ≥1 irAE(s), including 113 (12.2%) that were reported to be grade (G) 3 to 4 based on Common Terminology Criteria for Adverse Events (version 5.0). The median time to irAE onset was 9.8 weeks; 219 (57%) occurred within the first 3 months after ICI initiation. Discontinuation of treatment with ICIs owing to irAEs occurred in 137 (16.1%) patients. There was no significant difference in the rate of irAEs among patients aged younger than 85, 85 to 89, and 90 years or older. Despite the similar rate of G3 or higher irAEs, ICIs were discontinued due to irAEs more than twice as often among patients aged 90 years or older compared with patients younger than 90 years (30.9% vs 15.1%, P = .008). CONCLUSIONS AND RELEVANCE: The findings of this international cohort study suggest that treatment with ICIs may be effective and generally well tolerated among older patients with cancer, though ICI discontinuation owing to irAEs was more frequent with increasing age.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Nebhan CA, Cortellini A, Ma W, et al. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. JAMA Oncol. 2021. PMID: 34734989. doi:10.1001/jamaoncol.2021.4960

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。